PropertyValue
?:abstract
  • COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammatory agents. Herein, by analyzing prior efforts to advance antiviral mAbs for other acute respiratory infections (ARIs), we highlight the challenges faced by mAb-based immunotherapies for COVID-19. We present evidence supporting early intervention immediately following a positive diagnosis via inhaled delivery of mAbs with vibrating mesh nebulizers as a promising approach for the treatment of COVID-19.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1016/j.jconrel.2020.11.057
?:journal
  • J_Control_Release
?:license
  • no-cc
?:pdf_json_files
  • document_parses/pdf_json/175106ec774236800161df575a24741fb0bf9795.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7836766.xml.json
?:pmcid
?:pmid
?:pmid
  • 33276017.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Elsevier; Medline; PMC
?:title
  • Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19
?:type
?:year
  • 2021-01-10

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/q5nws0q8>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/q5nws0q8>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all